Neuronetics Inc

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Neuronetics reports robust Q4 performance, eyes nurse practitioner opportunities

Neuronetics delivered a strong performance in Q4 2022, showcasing revenue growth, operational achievements, and strategic partnerships.
While facing challenges in managing losses and revenue fluctuations, the company is focused on key initiatives and opportunities for future growth.
By leveraging upcoming opportunities with nurse practitioners and addressing analyst inquiries, Neuronetics aims to navigate challenges and drive sustainable growth in 2023.

Neuronetics Inc reports revenue growth and strategic advancements in Q1 2023

Neuronetics Inc's Q1 2023 performance reflects revenue growth, operational advancements, and strategic initiatives aimed at driving market expansion and financial stability.
While facing challenges in gross margin decline and negative EBITDA, the company's focus on cost management, recovery from merger disruption, and revenue guidance raise position it for future success.
With opportunities in expanded patient access, market growth, and product enhancements, Neuronetics is poised to capitalize on its strengths and navigate challenges effectively in the coming quarters.

Neuronetics reports solid Q2 performance, eyes growth amidst challenges

Neuronetics demonstrated resilience and growth in Q2 2023, with revenue increases and strategic advancements in technology and policy.
While facing challenges from closures and relocations, the company remains focused on financial stability and operational efficiency.
Opportunities lie in new technology clearances, favorable policy changes, and the growing demand for TMS therapy education and services.
Overall, Neuronetics' performance, strengths, challenges, and opportunities position the company for continued growth and market impact.

Neuronetics Inc reports solid Q3 earnings, faces challenges in expenses

Neuronetics Inc (STIM) delivered a strong performance in Q3 2023, showcasing revenue growth and operational advancements.
While facing challenges in aligning revenue with operating expenses, the company maintains a solid financial position and pursues growth opportunities.
By focusing on enhancing patient care standards, expanding market reach, and optimizing financial performance, Neuronetics Inc aims to drive sustainable growth and value creation.

Neuronetics Inc posts record revenue in Q4 2023 earnings call

Neuronetics Inc delivered a strong Q4 performance with revenue growth and achieving positive cash flow for the first time. The company's focus on strategic initiatives, regulatory advancements, and revenue guidance for 2024 indicate a positive trajectory for growth and profitability.

Neuronetics Inc reports revenue growth and strategic partnerships in Q1

Neuronetics Inc's Q1 2024 performance reflects revenue growth, operational efficiency improvements, and a strong financial position.
Strengths include successful programs, strategic partnerships, and growth opportunities in new market segments.
Challenges in system sales and revenue collection highlight areas for improvement, while opportunities in market expansion and revenue growth are promising.
Overall, Neuronetics shows resilience, innovation, and a strategic focus on driving growth and improving patient outcomes.

Neuronetics Inc reports Q2 revenue decline, eyes growth opportunities

Neuronetics Inc faced revenue challenges due to a cybersecurity breach but showed resilience in key areas.
Strategic adjustments and positive program results indicate a focus on growth and market expansion.
Acquisition and new debt facility offer opportunities for future expansion and financial stability.

Neuronetics reports solid Q3 earnings, eyes profitability and growth

Neuronetics is focused on optimizing operations, profitability, and cash flow breakeven by Q3 2025.
Greenbrook acquisition approval and strong business position provide a foundation for future growth.
Challenges include managing treatment session weakness and debt levels while pursuing revenue growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.

Coverage criteria consistent with recent FDA clearance for NeuroStar TMS Coverage criteria consistent with recent FDA clearance for NeuroStar TMS

Aetna Policy Update Expands TMS Availability for Adolescents With Depression

Medtronic

NeuroOne Medical Technologies Corp

If the prospect of controlling computers and robots with brainpower alone excites you, neurotech stocks are right up your alley. Unfortunately, today's top neurotech company — Elon Musk's Neuralink — remains off-limits to retail investors.

3 Neurotech Stocks Bridging Mind and Machine

NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-Cal

California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults

Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health Updated criteria post-FDA clearance for NeuroStar TMS benefit youth mental health

BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents

Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.

Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch

The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry The first and only TMS company to establish comprehensive standards for patient care and responsiveness in the mental health industry

NeuroStar® Launches Better Me Provider Program Nationwide

Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024 Early prediction of nonresponse abstract selected for oral presentation as a prestigious Top 4 Abstract at CTMSS 2024

NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting

MALVERN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Thursday, June 6, 2024. The Company is scheduled to present at 10:00am Central Time the same day via webcast.

Neuronetics to Present at the William Blair 44th Annual Growth Stock Conference

Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older Policy change comes quickly after FDA clearance for NeuroStar TMS use in ages 15 and older

Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents

Neuronetics, Inc. (NASDAQ:STIM ) Q1 2024 Results Conference Call May 7, 2024 8:30 AM ET Company Participants Mark Klausner - Investor Relations Keith Sullivan - President, Chief Executive Officer Steve Furlong - Chief Financial Officer Conference Call Participants Adam Maeder - Piper & Sandler Margaret Kaczor - William and Blair Danny Stauder - Citizens JMP Operator Thank you for standing by. Welcome to the Neuronetics First Quarter 2024 Conference Call.

Neuronetics, Inc. (STIM) Q1 2024 Earnings Call Transcript

Neuronetics (STIM) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.38 per share a year ago.

Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates

MALVERN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the first quarter of 2024.

Neuronetics Reports Record First Quarter 2024 Financial and Operating Results

The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance The Company is highlighting stories from adolescents with major depressive disorder on the heels of groundbreaking FDA clearance

NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month

MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/i3t5h9gs . To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar is also indicated as a first-line, adjunct for MDD in adolescents 15 and older. NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 6.1 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com. Investor Contact: Mike Vallie or Mark KlausnerICR Westwicke443-213-0499ir@neuronetics.com Media Contact: EvolveMKD646-517-4220NeuroStar@evolvemkd.com

Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call

Lack of early symptom improvement is not predictive of final responder status Lack of early symptom improvement is not predictive of final responder status

New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital

Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.

Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression

NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and older

NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression

The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.

Neuronetics (STIM) Progresses in MRD and TRD With New Deal

MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers. Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients.

Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network

Neuronetics, Inc. (NASDAQ:STIM ) Q4 2023 Earnings Conference Call March 5, 2024 8:30 AM ET Company Participants Keith Sullivan - President, Chief Executive Officer Steve Furlong - Chief Financial Officer Mark Klausner - Investor Relations Conference Call Participants Adam Maeder - Piper Margaret Kaczor - William Blair William Plovanic - Canaccord Danny Stauder - Citizens JMP Operator Ladies and gentlemen, thank you for standing by. Welcome to the Neuronetics Report Fourth Quarter 2023 Financial and Operating Results.

Neuronetics, Inc. (STIM) Q4 2023 Earnings Call Transcript

Neuronetics (STIM) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.30 per share a year ago.

Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates

MALVERN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2023.

Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results

MALVERN, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2023 financial and operating results prior to market open on Tuesday, March 5th, 2024. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call

Advancements provide workflow efficiencies for NeuroStar® TMS providers Advancements provide workflow efficiencies for NeuroStar® TMS providers

Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System

MALVERN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced criteria changes by Lucet Health that increase access for patients with depression to receive transcranial magnetic stimulation (TMS), such as NeuroStar® Advanced Therapy.

News for Neuronetics Inc Stock (STIM)